A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Key Inclusion Criteria:

• Has signs/symptoms of CD for at least 90 days prior to screening

• Has a CDAI score of 220 to 450, with an average daily stool subscore ≥4 pointsand/or an average daily abdominal pain subscore of ≥2 points

• Has an SES-CD score of ≥6 (or an SES-CD score of ≥4 if CD is isolated to the ileum)

• Demonstrated an inadequate response, loss of response, or intolerance to at leastone of the following treatments: Corticosteroids, Immunosuppressants (eg,azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for CD (eg,biologic agents, Janus kinase [JAK] inhibitors, applicable investigational products)

Key Exclusion Criteria:

• Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis,radiation colitis, or UC, or has clinical findings suggestive of UC

• Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianalregion, without colonic or ileal involvement

• Has had extensive bowel resection (>100 cm), and/or more than 3 resections, and/orhas a known diagnosis of short bowel syndrome

• Is currently receiving total parenteral nutrition, tube feeding, or a formula diet

• Has positive findings on a subjective neurological screening questionnaire

• Has a concurrent, clinically significant, serious, unstable comorbidity

• Previous treatment with vedolizumab or other licensed or investigational integrininhibitors

• Is currently participating in any other interventional study or has received anyinvestigational therapy within 30 days

• Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with asimilar mechanism to MORF-057

• Unable to attend study visits or comply with study procedures

• Has a history of any major neurological disorders, including: stroke, multiplesclerosis, brain tumor, demyelinating, or neurodegenerative disease